NEW YORK, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
XPO Logistics, Inc. (NYSE: XPO)
Class Period: February 26, 2014 - December 12, 2018
Lead Plaintiff Deadline: February 12, 2019
Join the action: https://www.zlk.com/pslra-1/xpo-logistics-inc-loss-form?wire=3
The lawsuit alleges: XPO Logistics, Inc. made materially false and/or misleading statements throughout the class period and/or
failed to disclose that: (i) XPO’s highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii)
XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad
debts and aggressive amortization assumptions; and (iii) as a result, the Company’s public statements were materially false and
misleading at all relevant times.
To learn more about the XPO Logistics, Inc. class action contact jlevi@levikorsinsky.com.
Teladoc Health, Inc. (NYSE: TDOC)
Class Period: March 3, 2016 - December 5, 2018
Lead Plaintiff Deadline: February 11, 2019
Join the action: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-form?wire=3
The lawsuit alleges: Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i)
Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an inappropriate sexual relationship with a
subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue benefits; (iii)
Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting the Company’s
operations; (iv) the Company’s enforcement of its own purported employment and trading policies were inadequate to prevent the
foregoing conduct; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant
times.
To learn more about the Teladoc Health, Inc. class action contact jlevi@levikorsinsky.com.
Dentsply Sirona, Inc. (NASDAQ: XRAY)
Class Period: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20,
2014 and August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2,
2015 and were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International
Inc. shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange
for their shares of common stock of Sirona in connection with the Acquisition
Lead Plaintiff Deadline: February 9, 2019
Join the action: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-form?wire=3
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s
“innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told
investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the
Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that
suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply.
Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson
Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result,
by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the
Company’s reported sales, financial results and guidance materially false and misleading. In addition, the Company
represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting
principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP
because it did not reflect the financial impact of the anticompetitive scheme.
To learn more about the Dentsply Sirona, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
